577 related articles for article (PubMed ID: 37503797)
1. Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions.
Larfors G; Andersson P; Jesson G; Liljebris C; Brisander M; Lennernäs H; Stenke L
Eur J Haematol; 2023 Oct; 111(4):644-654. PubMed ID: 37503797
[TBL] [Abstract][Full Text] [Related]
2. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
4. Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients.
Takahashi N; Miura M; Niioka T; Sawada K
Cancer Chemother Pharmacol; 2012 Apr; 69(4):999-1004. PubMed ID: 22147077
[TBL] [Abstract][Full Text] [Related]
5. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
6. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Keam SJ
BioDrugs; 2008; 22(1):59-69. PubMed ID: 18215092
[TBL] [Abstract][Full Text] [Related]
7. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
8. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Osorio S; Escudero-Vilaplana V; Gómez-Centurión I; Pérez-López R; Ayala R; Vall-Llovera F; García-Gutierrez V; Gómez Casares MT; González San Miguel JD; Hernández-Rivas JÁ; Sánchez-Guijo F; Martínez-García AB; Villalón L; Conesa-García V; Rodriguez A; Casado F; Garcia-Gonzalez X; Sáez Perdomo MN; Baños Ú; Steegmann JL;
Ann Hematol; 2018 Nov; 97(11):2089-2098. PubMed ID: 29955943
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Generic Dasatinib as a Second-line Treatment for Patients with Chronic Myeloid Leukemia: a Multicenter Retrospective Study in Hubei Province, China.
Chen LF; Yuan GL; Zhong ZD; Zou P; Li DJ; Bao Y; Ren HB; Meng L; Li WM
Curr Med Sci; 2018 Dec; 38(6):1005-1011. PubMed ID: 30536062
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study.
Iwamoto T; Monma F; Ohishi K; Umino A; Suzuki K; Oka K; Kawakami K; Sekine T; Okuda M; Katayama N
Ther Drug Monit; 2019 Oct; 41(5):575-581. PubMed ID: 31008998
[TBL] [Abstract][Full Text] [Related]
11. The Impact of Tyrosine Kinase Inhibitors on Chronic Myeloid Leukemia Stem Cells and the Implication in Discontinuation.
Jiang L; Wang H; Zhu X; Liu W; Zhou S; Geng Z; Xiao Y; Zou P; You Y; Li Q; Zhu X
Stem Cells Dev; 2019 Nov; 28(22):1480-1485. PubMed ID: 31530245
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: a guide to its use in chronic myeloid leukemia in the EU.
Keating GM; Lyseng-Williamson KA; McCormack PL; Keam SJ
BioDrugs; 2013 Jun; 27(3):275-9. PubMed ID: 23549840
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary hypertension in patients with chronic myeloid leukemia.
Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Sun BJ; Park JH; Jeong JO; Jo DY
Medicine (Baltimore); 2021 Aug; 100(33):e26975. PubMed ID: 34414970
[TBL] [Abstract][Full Text] [Related]
14. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
15. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
16. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
17. The role of dasatinib in the management of chronic myeloid leukemia.
Chen R; Chen B
Drug Des Devel Ther; 2015; 9():773-9. PubMed ID: 25709401
[TBL] [Abstract][Full Text] [Related]
18. Influence of proton pump inhibitors and H2-receptor antagonists on the efficacy and safety of dasatinib in chronic myeloid leukemia patients.
Koutake Y; Taniguchi J; Yasumori N; Nagaishi H; Eto T; Nakashima K; Fukazawa M; Hayashi T
Int J Hematol; 2020 Jun; 111(6):826-832. PubMed ID: 32152877
[TBL] [Abstract][Full Text] [Related]
19. Chronic myeloid leukemia (CML): association of treatment satisfaction, negative medication experience and treatment restrictions with health outcomes, from the patient's perspective.
Hirji I; Gupta S; Goren A; Chirovsky DR; Moadel AB; Olavarria E; Victor TW; Davis CC
Health Qual Life Outcomes; 2013 Oct; 11():167. PubMed ID: 24099272
[TBL] [Abstract][Full Text] [Related]
20. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]